CONCLUSIONS
viremia
VIREMIA
Apart from COVID-19–related challenges, it was feasible to conduct a trial of point-of-care VL testing to manage viremia. Point-of-care testing reduced time to results and clinical visits, but point-estimates of 24-week viral resuppression were similar to the standard-of-care arm. Larger studies are needed to assess clinical outcomes and to identify potential interventions for people with viremia in the context of the ongoing dolutegravir rollout.